Trastuzumab emtansine for adjuvant treatment of HER2-positive early breast cancer: Final appraisal document

DRAFT guidance recommends trastuzumab emtansine for adjuvant treatment of HER2-positive early breast cancer in adults who have residual invasive disease in breast or lymph nodes after neoadjuvant taxane-based and HER2-targeted therapy, according to the commercial arrangement.

Source:

National Institute for Health and Care Excellence